IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v25y2024i3d10.1007_s10198-023-01590-x.html
   My bibliography  Save this article

Cost-effectiveness of transcatheter aortic valve implantation in patients at low surgical risk in France: a model-based analysis of the Evolut LR trial

Author

Listed:
  • Didier Tchétché

    (Clinique Pasteur)

  • Coline Dubois Gennes

    (Amaris)

  • Quentin Cormerais

    (Medtronic, Plc)

  • Benjamin P. Geisler

    (Massachusetts General Hospital, Harvard Medical School
    Wing Tech Inc.)

  • Camille Dutot

    (Medtronic, Plc)

  • Fanny Wilquin-Bequet

    (Medtronic, Plc)

  • Manon Breau-Brunel

    (Amaris)

  • Béranger Lueza

    (Amaris)

  • Jan B. Pietzsch

    (Wing Tech Inc.)

Abstract

Background In the recent Evolut Low Risk randomized trial, transcatheter aortic valve implantation (TAVI) was shown to be non-inferior to surgery (SAVR) regarding the composite end point of all-cause mortality or disabling stroke at 24 months. Aims To evaluate the cost-effectiveness of self-expandable TAVI in low-risk patients, using the French healthcare system as the basis for analysis. Methods Mortality, health-related quality of life, and clinical event rates through two-year follow-up were derived from trial data (N = 725 TAVI and N = 678 SAVR; mean age: 73.9 years; mean STS-PROM: 1.9%). Cost inputs were based on real-world data for TAVI and SAVR procedures in the French healthcare system. Costs and effectiveness as quality-adjusted life years (QALYs) were projected to lifetime via a decision-analytic model under assumption of no mortality difference beyond two years. The discounted incremental cost-effectiveness ratio (ICER) was evaluated against a willingness-to-pay threshold of €50,000 per QALY gained. Deterministic and probabilistic sensitivity analyses were conducted, including assumptions about differential long-term survival. Results For the base case, mean survival was 13.69 vs 13.56 (+ 0.13) years for TAVI and SAVR, respectively. Discounted QALYs were 9.34 vs. 9.21 (+ 0.13) and discounted lifetime costs €52,267 vs. €51,433 (+ €833), resulting in a lifetime ICER of €6368 per QALY gained. In probabilistic sensitivity analysis, TAVI was found dominant or cost-effective in 74.4% of samples. Conclusion TAVI in patients at low surgical risk is a cost-effective alternative to SAVR in the French healthcare system. Longer follow-up data will help increase the accuracy of lifetime survival projections. Graphical Abstract

Suggested Citation

  • Didier Tchétché & Coline Dubois Gennes & Quentin Cormerais & Benjamin P. Geisler & Camille Dutot & Fanny Wilquin-Bequet & Manon Breau-Brunel & Béranger Lueza & Jan B. Pietzsch, 2024. "Cost-effectiveness of transcatheter aortic valve implantation in patients at low surgical risk in France: a model-based analysis of the Evolut LR trial," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 25(3), pages 447-457, April.
    • Handle: RePEc:spr:eujhec:v:25:y:2024:i:3:d:10.1007_s10198-023-01590-x
    DOI: 10.1007/s10198-023-01590-x
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s10198-023-01590-x
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s10198-023-01590-x?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Julie Chevalier & Gérard Pouvourville, 2013. "Valuing EQ-5D using Time Trade-Off in France," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 57-66, February.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Marguerite Kandel & Aurélie Bardet & Stéphane Dalle & Clara Allayous & Laurent Mortier & Bernard Guillot & Caroline Dutriaux & Marie-Thérèse Leccia & Sophie Dalac & Henri Montaudié & Philippe Saiag & , 2022. "Cost-Effectiveness Analysis of Sequential Treatment Strategies for Advanced Melanoma in Real Life in France," Post-Print hal-04049403, HAL.
    2. Karine Chevreul & Coralie Gandré & Karen Berg Brigham & Julio López-Bastida & Renata Linertová & Juan Oliva-Moreno & Pedro Serrano-Aguilar & Manuel Posada-de-la-Paz & Domenica Taruscio & Arrigo Schiep, 2016. "Social/economic costs and health-related quality of life in patients with fragile X syndrome in Europe," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(1), pages 43-52, April.
    3. Mathieu F. Janssen & A. Simon Pickard & James W. Shaw, 2021. "General population normative data for the EQ-5D-3L in the five largest European economies," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(9), pages 1467-1475, December.
    4. Manuel B. Huber & Julia Felix & Martin Vogelmann & Reiner Leidl, 2017. "Health-Related Quality of Life of the General German Population in 2015: Results from the EQ-5D-5L," IJERPH, MDPI, vol. 14(4), pages 1-12, April.
    5. Laurène Gautier & Jessica Azzi & Grèce Saba & Geneviève Bonnelye & Gérard Pouvourville, 2023. "Population norms in France with EQ-5D-5L: health states, value indexes, and VAS," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(9), pages 1517-1530, December.
    6. Marian Sorin Paveliu & Elena Olariu & Raluca Caplescu & Yemi Oluboyede & Ileana-Gabriela Niculescu-Aron & Simona Ernu & Luke Vale, 2021. "Estimating an EQ-5D-3L Value Set for Romania Using Time Trade-Off," IJERPH, MDPI, vol. 18(14), pages 1-16, July.
    7. Fan Yang & Carlos K. H. Wong & Nan Luo & James Piercy & Rebecca Moon & James Jackson, 2019. "Mapping the kidney disease quality of life 36-item short form survey (KDQOL-36) to the EQ-5D-3L and the EQ-5D-5L in patients undergoing dialysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(8), pages 1195-1206, November.
    8. Gregoire Mercier & Jenica Pastor & Valerie Clément & Ulysse Rodts & Christine Moffat & Isabelle Quéré, 2019. "Out-of-pocket payments, vertical equity and unmet medical needs in France: A national multicenter prospective study on lymphedema," PLOS ONE, Public Library of Science, vol. 14(5), pages 1-13, May.
    9. Tessier, Philippe & Blanchin, Myriam & Sébille, Véronique, 2017. "Does the relationship between health-related quality of life and subjective well-being change over time? An exploratory study among breast cancer patients," Social Science & Medicine, Elsevier, vol. 174(C), pages 96-103.
    10. Marine Sivignon & Rémi Monnier & Bertrand Tehard & Stéphane Roze, 2020. "Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France," PLOS ONE, Public Library of Science, vol. 15(1), pages 1-14, January.
    11. Grégoire Mercier & Jenica Pastor & Valérie Clément & Ulysse Rodts & Christine Moffat & Isabelle Quéré, 2019. "Out-of-pocket payments, vertical equity and unmet medical needs in France: A national multicenter prospective study on lymphedema," Post-Print hal-02862217, HAL.
    12. Julie Chevalier & Catherine Chamoux & Florence Hammès & Annie Chicoye, 2016. "Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective," PLOS ONE, Public Library of Science, vol. 11(3), pages 1-12, March.
    13. Anne Spencer & Ewan Tomeny & Ruben E. Mujica-Mota & Angela Robinson & Judith Covey & Jose Luis Pinto-Prades, 2019. "Do time trade-off values fully capture attitudes that are relevant to health-related choices?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(4), pages 559-568, June.

    More about this item

    Keywords

    Aortic valve stenosis; Transcatheter aortic valve implantation; Surgical aortic valve replacement; Cost–benefit analysis; Health-related quality of life; France;
    All these keywords.

    JEL classification:

    • I13 - Health, Education, and Welfare - - Health - - - Health Insurance, Public and Private
    • I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health
    • H51 - Public Economics - - National Government Expenditures and Related Policies - - - Government Expenditures and Health

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:25:y:2024:i:3:d:10.1007_s10198-023-01590-x. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.